Intravenous Tissue-Type Plasminogen Activator for Treatment of Acute Stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) Study

Article Abstract:

Tissue-type plasminogen activator (t-PA) may be beneficial for treating stroke. t-PA breaks up blood clots, which are the cause of most strokes. Researchers gave 389 patients with the symptoms of a stroke intravenous alteplase. Alteplase is a synthetic form of tPA. Thirty days after their stroke, 35% of the patients were doing well and 43% were capable of taking care of themselves. Eight percent had bleeding in their brain, which is a side effect of t-PA.

---

Use of Tissue-Type Plasminogen Activator for Acute Ischemic Stroke: The Cleveland Area Experience

Article Abstract:

Tissue-type plasminogen activator (tPA) may not benefit many stroke patients. tPA breaks down blood clots, which cause most strokes. Of 3,948 patients admitted to a hospital with symptoms of a stroke, 70 received tPA. Eleven developed bleeding in the brain, which killed six. Bleeding in the brain is a known complication of tPA treatment. Sixteen percent of the patients who received tPA died, compared to 8% of those who did not receive tPA.

---

Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset: The ATLANTIS Study: A Randomized Controlled Trial

Article Abstract:

Recombinant tissue-type plasminogen activator (rt-PA) does not appear to improve the outcome of stroke patients when given more than 3 hours after the stroke began. Researchers randomly assigned 547 stroke patients to receive a one-hour intravenous infusion of rt-PA or a placebo between 3 to 5 hours after the stroke began. About one-third of both groups had recovered three months later. Patients who received rt-PA were more likely to develop bleeding in the brain and more likely to die within three months compared to those who received a placebo, or inactive substance.

Drug therapy

Similar abstracts:

• Abstracts: Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: A randomized controlled trial
• Abstracts: Recombinant Glycoprotein Vaccine for the Prevention of Genital HSV-2 Infection: Two Randomized Controlled Trials
• Abstracts: Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. Trends in the Prescribing of Psychotropic Medications to Preschoolers
• Abstracts: Impaired activity of protease inhibitors towards neutrophil elastase bound to human articular cartilage. Cyclopentenone prostaglandins -- new allies in the war on inflammation
• Abstracts: The dental unit waterline controversy: defusing the myths, defining the solution. Dental unit waterline antimicrobial agents' effect on dentin bond strength

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.